ZIOPHARM Palifosfamide PICASSO Trial Abstract Selected for 2010 Best of ASCO® Meeting Program <<ASCO = American Society of Clinical Oncology>>NEW YORK--(BUSINESS WIRE)-- ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that its abstract, “A phase II randomized controlled trial of palifosfamide plus doxorubicin vs. doxorubicin in patients with soft tissue sarcoma (PICASSO)”, to be presented at the 2010 ASCO Annual Meeting, has been selected as part of the 2010 Best of ASCO® educational program. Best of ASCO® sessions will be held in both San Francisco and Boston in the United States and in several countries around the world in the months following the ASCO Annual meeting, which is taking place this year June 4th-8th in Chicago.According to ASCO, the 2010 Best of ASCO® program promises to feature topics that highlight the latest scientific findings and practice-changing advances in cancer prevention and treatment, allowing faculty members to provide a clinical context for this new scientific information. These sessions appeal to subspecialties in oncology and provide a unique forum for this information to be discussed.Smufty (long ZIOP)
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ra